executive summary

Treating underserved patients

The platform helps patients navigate the complex process of obtaining GLP-1 medications by providing them with seamless and user-friendly experiences optimized for the unique needs of each target demographic.

Read More

$100B

Projections for the global obesity therapeutic market by 2030 and $200 billion over the next decade.

With the global therapeutic market for obesity projected to reach $200 billion over the next decade, FWD is well-positioned to capitalize on this growth with its agile platform, distributed supply chain, and experienced team. We’re currently raising $2 million to launch and scale the initial prescribing brands in Jan 2024.

our strategy

An end-to-end treatment platform for generic meds

FWD (Forward) is a healthcare technology company that provides convenient access to revolutionary GLP-1 semaglutides and tirzepatides, the main ingredient in Ozempic, Wegovy, Mounjaro and Zepbound.

DTC

The FWD platform offers an end-to-end solution for qualified patients: from telehealth appointments with licensed providers to determine medical necessity, to prescription, and order fulfillment through FDA-certified, mail-order compound pharmacy partners.

GLP-1

Medications that are proven safe and effective. Brand names known as Ozempic, Wegovy, Mounjaro, Zepbound

Beyond traditional segments

Incumbent DTC & Aesthetic Spas aim to aggressively acquire the highest LTV user segments early in the adoption cycle of GLP-1 drugs, especially users with high discretionary spending on general health and wellness, whether with the participation of an insurance payer or not. These cohorts certainly include coastal, metropolitan, non-minority Millennial and Gen X users - but these are not the only large, valuable segments seeking immediate solutions to the health effects of being overweight or obese.

Read More

77%

of African American and Latino women in America are obese.

INTRODUCTION

Systemic health issues are creating drug scarcity

Emergency shortages of the Novo Nordisk medications Ozempic® and Wegovy® as well as the Eli Lilly drugs Mounjaro® and Zepbound® have led the FDA to grant mail-order compounding pharmacies authorization to produce and fill valid prescriptions for the generic alternatives of these branded drugs for the purpose of treating overweight, obese and severely obese patients.

Read More

42%

of all Americans are Obese (BMI > 30) 1, including 9.2% who are Severely Obese (BMI > 40).

$173B/yr

The cost of treating obesity-related health issues - including Heart Disease, Type-2 Diabetes & some cancers - has soared to $173 Billion per year in the US.

Delivering better solutions for longevity

Delivering better solutions for longevity

Delivering better solutions for longevity

Safe & convenient solutions for wellness and longevity. We digitally prescribe, prepare, and fulfill tailored medications across a variety of therapeutics.

Safe & convenient solutions for wellness and longevity. We digitally prescribe, prepare, and fulfill tailored medications across a variety of therapeutics.

limited access to meds

Systemic health issues are creating drug scarcity

Systemic health issues are creating drug scarcity

GLP receptor agonists (GLP-1) released in the early 2000s to treat diabetes have proven to be highly effective in weight-loss across broad populations. So much so that emergency shortages of the medication for diabetics has led the FDA to grant mail-order compounding pharmacies authorization to produce and fill valid prescriptions for the generic alternatives of these branded drugs for treating weight-loss.

Traditionally, these medications have been both expensive and difficult to come by for non-diabetics as consumption from the existing 37 million and growing US diabetics has strained the production capabilities of branded drug manufacturers.

42%

of all Americans are Obese (BMI > 30) 1, including 9.2% who are Severely Obese (BMI > 40).

$173B/yr

The cost of treating obesity-related health issues in the US - including Heart Disease, Type-2 Diabetes & some cancers

our strategy

An end-to-end treatment platform for generic meds

An end-to-end treatment platform for generic meds

FWD (Forward) is a healthcare technology company that provides virtual patient care and convenient direct-to-consumer access to life-altering meds like GLP-1 semaglutides and tirzepatides, which are proven, effective, and wildly popular for weight-loss under the brand names of Ozempic®, Wegovy®, Mounjaro®, Zepbound®, and others.

FWD (Forward) is a healthcare technology company that provides patients with convenient access to life-altering GLP-1 semaglutides and tirzepatides, which are proven, effective medications prescribed for weight-loss under the brand names of Ozempic, Wegovy, Mounjaro, Zepbound, and others.

The FWD platform offers an end-to-end solution for qualified patients: from telehealth appointments with licensed providers to determine medical necessity, to prescription, and order fulfillment through FDA-certified, mail-order compound pharmacy partners.

DTC

The FWD platform offers an end-to-end solution for qualified patients: from telehealth appointments with licensed providers to determine medical necessity, to prescription, and order fulfillment through FDA-certified, mail-order compound pharmacy partners.

GLP-1

FWD brands compound and deliver generic versions of medications that are proven safe and effective. Brand names known as Ozempic, Wegovy, Mounjaro, Zepbound

Serving largely underdeveloped patient cohorts

Treating underserved patients

FWD guides patients through a efficacy-focused UX and entirely virtual process including consultation, prescription, payment, and education. All fulfilled by FDA-certified compounding pharmacies.

$100 Billion

Projections for the global obesity therapeutic market by 2030 and $200 billion over the next decade.

$100B

Projections for the global obesity therapeutic market by 2030 and $200 billion over the next decade.

We are starting with GLP-1s, as obesity is a top comorbidity impacting disease in this country. The obesity therapeutic market alone is projected to reach $200 billion over the next decade, and FWD is well-positioned to address this growth with our agile platform and distributed supply chain.

We are starting with GLP-1s, as obesity is a top comorbidity impacting disease in this country. The obesity therapeutic market alone is projected to reach $200 billion over the next decade, and FWD is well-positioned to address this growth with our agile platform and distributed supply chain.

focus first on weight management

Going beyond traditional and
beauty segments

Going beyond traditional and
beauty segments

Incumbent DTC & Aesthetic Spas aim to aggressively acquire the highest LTV user segments early in the adoption cycle of GLP-1 drugs, especially users with high discretionary spending on general health and wellness, whether with the participation of an insurance payer or not. These cohorts certainly include coastal, metropolitan, non-minority Millennial and Gen X users - but these are not the only large, valuable segments seeking immediate solutions to the health effects of being overweight or obese.

Read More

Over 77%

of African American and Latino women in America are obese.


FWD is positioned to drive GLP-1 market growth from $10-20B per year in the US today to  $70-$90B globally by 2032.


People in the office
People in the office
People in the office

a longterm lifestyle solution

Solutions for
ongoing efficacy

Solutions for
ongoing efficacy

Solutions for
longterm efficacy

Despite the current headwinds to Direct to Consumer (DTC) and primarily eCommerce models, firms like Ro have been rewarded by the marketplace for their high-value, low-churn subscription prescription customers. Additionally Ro’s successful lifecycle marketing efforts have generated greater Long Term Value (LTV) from users initially acquired to prescribe sexual health medications through expansion to relevant adjacent verticals like hair loss, testosterone support and, recently, GLP-1 weight-loss drugs.

Read More

High-value, low-churn

Greater, captive LTV

B2B2C clinic distribution

the way we deliver

Simplified user journey & diversified
supply network

Simplified user journey & diversified
supply network

Leveraging APIs for a streamlined onboarding process, we can deliver a faster, more thoughtful intial interaction. Patients can go from sign-in to prescription in a single session, with meds out for delivery same-day. Fulfillment is powered by a diversified supply chain of compounding pharmacies, preventing risk of back order. Refills bill and ship automatically until a prescription renewal is required, at which point the renewal consultation is facilitated automatically as well.

Read More

The patient journey guides a customer through the initial web-based consultation and prescription transfer to compounding pharmacy for fulfillment - all during a single interaction. The first medication arrives as soon as the same week and monthly refills bill and ship automatically until a prescription renewal is required, at which point the renewal consultation is facilitated automatically as well.

Read More

The patient journey guides a customer through the initial web-based consultation and prescription transfer to compounding pharmacy for fulfillment - all during a single interaction. The first medication arrives as soon as the same week and monthly refills bill and ship automatically until a prescription renewal is required, at which point the renewal consultation is facilitated automatically as well.

Read More

house of brands

One platform powering brands designed for unique user experiences

FWD Care brands are designed to better focus our care on customer groups' specific needs and experience expectations.

house of brands

One platform powering unique user experiences

One platform powering brands designed for unique experiences

FWD Care brands focus on providing tailored care based on customer groups' specific needs and expectations.

FWD Care brands focus on providing tailored care based on customer groups' specific needs and expectations.

financials and raising info

Built to rapidly
scale profitability

Built to rapidly
scale profitability

DTC businesses depend on high-value, low-churn customers. These dynamics enable FWD to aggressively acquire users - snowballing as a return and recurring subscriber base scales, and cross-selling is operationalized.

Our business model thrives on high-value, low-churn, enabling FWD to aggressively acquire users— early and recurring— in a macro environment where many consumer brands are struggling to find efficient growth channels.

Seeking to Raise

to accelerate pre-launch product, marketing and brand development as well as fund user acquisition through launch and to self-sufficiency over an 18-month ramp timeline. In addition to a standard equity-raise trigger for conversion of the SAFE, the convertible note offered to founding investors also includes participation rights in general equity distributions, producing investor returns prior to any liquidity event.

For detailed financials, contact Rob Horowitz

Seeking to Raise

to accelerate pre-launch product, marketing and brand development as well as fund user acquisition through launch and to self-sufficiency over an 18-month ramp timeline. In addition to a standard equity-raise trigger for conversion of the SAFE, the convertible note offered to founding investors also includes participation rights in general equity distributions, producing investor returns prior to any liquidity event.

contact Rob Horowitz

Seeking to Raise

to accelerate pre-launch product, marketing and brand development as well as fund user acquisition through launch and to self-sufficiency over an 18-month ramp timeline. In addition to a standard equity-raise trigger for conversion of the SAFE, the convertible note offered to founding investors also includes participation rights in general equity distributions, producing investor returns prior to any liquidity event.

For detailed financials, contact Rob Horowitz

Lean Expert Team

Progress is neither today gated by requirement for large headcount nor does payroll expense project to exceed 10% of revenue at any point after the initial scale-up period post-launch in January 2024.

Right Timing

Explosive projected growth in the GLP-1 category kickstarts a profitable flywheel as swift pay-back and profitability from earlier subscribers funds acquisition of subsequent users.

De-risked Supply Chain

FWD also significantly defrays the inventory risk inherent to virtually every other DTC model through its on-demand manufacturing network of compounding pharmacies; this distributed supply chain ensures resilience against disruption and consistent service levels to patients.

And more is coming

And more is coming

And more is coming

Semaglutide Oral

Semaglutide Oral

no more needles!

no more needles!

Hormone Therapy

Coming soon

Coming soon

Hair Loss

Coming soon

Coming soon

Sexual Wellness

Coming soon

Fertility Treatments

Coming soon

Mental Health

Coming soon

Sexual Wellness

Coming soon

Fertility Treatments

Coming soon

Mental Health

Coming soon

our prescribing technologY

our technologY

our technologY

Results for way less,
access to way more

Results for way less,
access to way more

Our distributed network of compounding pharmacies, and a robust digital prescribing platform give FWD competitive strengths enabling us to serve multiple patient cohorts today as well as continuously identify & launch resonant prescribing brands in adjacent medication verticals using our existing pharmacy and platform technologies.  

Treatment less than most insurances*

Compared to insurance prices that range
from $700-1200/month.

Compared to insurance prices that range
from $700-1200/month.

Get notified when your meds are ready

We notify you when your prescription is filled, and when it is on its way to your door.

We notify you when your prescription is filled, and when it is on its way to your door.

Start and stop anytime

Pause your treatment anytime, and restart whenever you're ready without having to recreate your plan.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

// Protocol

start security-1, { Schema } from 'secure portal'


// Efficiency

apply rel group = 'Develop'|


// Shield

debug platform = rep Schema({

start: {

variant: String,

required: true

},


description: {

type: String

}

}, {timestamps: true})


// Model

export default untitled.model(collection, schema, collection)


Secure and reliable

Our platform is HIPAA-certified and secure using LegitScripts.

Integrated Messaging

Talk to us anytime via the platform, or reach out on Whatsapp,

Longevity,

delivered.

Longevity,

delivered.

All rights reserved FWD Care, LLC. Copyright© 2023

Contact Us

All rights reserved FWD Care, LLC. Copyright© 2023

Contact Us

All rights reserved FWD Care, LLC. Copyright© 2023

Contact Us